Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adipose stem cell therapy - Anterogen

Drug Profile

Adipose stem cell therapy - Anterogen

Alternative Names: Allogeneic mesenchymal stem cells - Anterogen; Adipocell (Anterogen); AdipoPlus; Adipose-derived stem cells; ALLO-ASC; ALLO-ASC-DFU; ALLO-ASC-EB; ALLO-ASC-OA; ALLO-ASC-SHEET; ALLO-ASC-TI; Allogeneic adipose stem cells; ANTG-ASC; Autologous adipose stem cells; Cupistem; Queencell

Latest Information Update: 20 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anterogen
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rectal fistula; Scars; Subcutaneous fat disorders
  • Phase III Crohn's disease; Diabetic foot ulcer
  • Phase I/II Tendon injuries
  • No development reported Burns; Chronic wounds; Epidermolysis bullosa; IgA nephropathy; Osteoarthritis

Most Recent Events

  • 15 Dec 2021 Anterogen plans a phase II trial for Epidermolysis Bullosa (In children, In adults, In adolescents, In elderly) in January 2022 (Parenteral) (NCT05157958)
  • 25 Feb 2021 Phase-II development is ongoing in Diabetic foot ulcer in USA (Parenteral) (NCT03754465)
  • 25 Feb 2021 Phase-III development is ongoing in Diabetic foot ulcer in South Korea (Parenteral) (NCT03370874)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top